A CANADIAN VETERINARY LIFE SCIENCES INITIATIVE

Advancing Veterinary Cannabinoid Science

PuralisVET is building a Canadian veterinary research and development pathway designed to advance cannabinoid science from biological understanding and existing veterinary evidence through controlled investigation, regulatory development and, if supported by the evidence, future commercialization of a regulated veterinary medicine.

From biological discovery to veterinary evidence.

Explore the Science Our Development Path

A veterinary life sciences initiative of CannaGenetics Inc.

THE CANINE ENDOCANNABINOID SYSTEM

A Biological System With Broad Physiological Relevance

The canine endocannabinoid system is a widespread biological signalling network involved in maintaining physiological balance across multiple tissues and organ systems. Its distribution throughout the body provides an important scientific foundation for understanding cannabinoid pharmacology in veterinary medicine.

Cannabinoids such as CBD may act through multiple biological pathways beyond the classical cannabinoid receptors CB1 and CB2, including cannabinoid related molecular targets that continue to be investigated in veterinary medicine. This complexity is one reason controlled investigation is essential.

ECS activity and research spans multiple biological systems

Nervous systemImmune systemGastrointestinal systemSkinMusculoskeletal system

Scientific visualization of the canine endocannabinoid system

Scientific cannabinoid signalling visualization

BUILDING ON EXISTING VETERINARY SCIENCE

Advancing What the Science Has Already Started

Published veterinary research has begun to build an important scientific foundation for cannabinoid investigation in dogs. Clinical studies in canine osteoarthritis have reported encouraging findings, while pharmacokinetic, safety and biological research continues to expand our understanding of cannabinoids in veterinary medicine.

PuralisVET is building on this existing body of science to address the questions that remain and generate the evidence required for future veterinary drug development.

Existing Clinical Evidence

Published canine studies contribute to a growing body of clinical research investigating cannabinoids in osteoarthritis and chronic pain.

Canine Biology

Research continues to improve understanding of the endocannabinoid system, cannabinoid related targets and their relevance to canine physiology and joint health.

Questions That Remain

Further controlled investigation is required to strengthen understanding of safety, efficacy, dosing, product quality and clinically meaningful outcomes.

The Next Evidence Step

PuralisVET intends to build on the existing science through a structured veterinary development program designed to generate evidence capable of supporting future regulatory review.

INITIAL VETERINARY DEVELOPMENT FOCUS

Beginning With Canine Osteoarthritis

Canine osteoarthritis is a common, progressive joint disease that can significantly affect mobility, comfort and quality of life.

It is also one of the most studied areas of veterinary cannabinoid research, with published canine studies providing an important clinical and scientific foundation for further investigation.

PuralisVET has selected canine osteoarthritis as its initial development indication, with the objective of building on this existing science through controlled veterinary studies and generating the evidence required to support future regulatory review.

Why canine osteoarthritis?

Established clinical need. A common chronic condition affecting mobility and quality of life in dogs.

Existing veterinary evidence. Published canine studies provide a scientific and clinical foundation for further investigation.

Clear development path. A focused indication enables controlled investigation, evidence generation and regulatory development.

Canine synovial tissue evidence for CB1, CB2 and GPR55

FROM SCIENCE TO VETERINARY DEVELOPMENT

Moving the Science Forward

PuralisVET is advancing its canine osteoarthritis program from proposed proprietary formulations through controlled clinical investigation, evidence generation, regulatory review and, if authorized, commercialization.

DEVELOPINVESTIGATEADVANCE

Proposed Proprietary Formulations

PuralisVET has developed proposed proprietary veterinary cannabinoid formulations informed by published canine research, cannabinoid science and existing clinical evidence.

Clinical Program Development

Building the controlled clinical program required to investigate the proposed formulations in canine osteoarthritis, including study design, clinical endpoints and veterinary oversight.

Regulatory Authorization

Advance the investigational program through Health Canada’s Experimental Studies Certificate pathway to enable controlled veterinary investigation.

Clinical Investigation & Data

Conduct controlled veterinary studies to evaluate safety, efficacy and clinically meaningful outcomes and generate the data required to assess the program.

Regulatory Review

If the resulting evidence is supportive, advance the program and supporting data through the applicable veterinary drug regulatory pathway.

Authorization & Commercialization

Subject to successful regulatory review and authorization, advance the veterinary medicine toward commercialization in Canada.

EVIDENCE DRIVES DEVELOPMENT

Building the Evidence for a Regulated Veterinary Medicine

Regulatory development requires more than promising science. It requires a structured body of evidence demonstrating that an investigational veterinary medicine can meet appropriate standards for safety, efficacy and quality.

PuralisVET’s development program is intended to generate this evidence systematically through controlled veterinary investigation, rigorous data collection and appropriate scientific and regulatory oversight.

Safety

Evaluate tolerability, adverse events, hepatic parameters and other relevant safety measures under controlled veterinary investigation.

Efficacy

Evaluate clinically meaningful outcomes using controlled study design and validated veterinary outcome measures relevant to canine osteoarthritis.

Quality

Establish the consistency, characterization and quality controls required for an investigational product intended for veterinary drug development.

Clinical Evidence

Generate well documented veterinary data capable of informing future study design, regulatory decisions and continued development.

STRATEGIC VETERINARY COLLABORATION

Advancing Veterinary Medicine Together

PuralisVET has developed its proposed proprietary veterinary cannabinoid formulations and established canine osteoarthritis as its initial development indication. The program is now advancing toward the clinical stage.

We are engaging veterinary leaders, clinical institutions and scientific partners who can contribute their expertise to the next phase of development and help advance the program toward controlled investigation and regulatory review.

✚

Veterinary Leadership

Working with experienced veterinary professionals and clinical investigators to help guide the program through its next stage.

◇

Clinical Partnerships

Engaging leading veterinary institutions capable of participating in controlled clinical investigation of canine osteoarthritis.

⌬

Scientific Collaboration

Bringing together complementary scientific, research and regulatory expertise as the program advances.

JOIN THE NEXT STAGE

PuralisVET welcomes discussions with veterinary leaders, clinical institutions and research organizations interested in participating in the advancement of evidence based cannabinoid medicine for animal health.

Discuss a Collaboration

THE COMPANY BEHIND PURALISVET

Developed by CannaGenetics Inc.

PuralisVET is the veterinary life sciences initiative of CannaGenetics Inc., a Canadian company developing cannabinoid based research, development and manufacturing capabilities for human and veterinary applications.

Through PuralisVET, CannaGenetics is applying its scientific and development capabilities to a focused objective: advancing veterinary cannabinoid research toward regulated veterinary medicine.

CANNAGENETICS

Canadian science. Veterinary development.
A pathway toward regulated medicine.

FROM RESEARCH TO REGULATED VETERINARY MEDICINE

Building Toward Commercialization

PuralisVET is not pursuing research as an endpoint. The program is being developed with the objective of translating veterinary cannabinoid science into a regulated veterinary medicine for canine osteoarthritis.

Through the Experimental Studies Certificate pathway, controlled veterinary investigation and the generation of appropriate safety, efficacy and quality evidence, PuralisVET intends to build the regulatory foundation required to pursue market authorization in Canada.

If the evidence supports the program and regulatory authorization is achieved, the objective is commercialization.

BUILDING THE EVIDENCE FOR VETERINARY MEDICINE

The Future Must Be Built on Evidence.

PuralisVET is working to help establish a new category of evidence based veterinary cannabinoid medicine, beginning with canine osteoarthritis.

SCIENCE. • EVIDENCE. • ANIMAL HEALTH.
Contact PuralisVET